AbbVie Archives - OGP News

9 June 2026

NICE recommends first-in-class FRα ADC in platinum-resistant ovarian cancer

This is a further step towards biomarker-driven treatment in ovarian cancer. AbbVie recently announced that the National Institute for Health and...

BROWSE BY SECTION

ANALYSIS
APRIL 2026
ARTICLES
COMPANIES
COMPANY INTERVIEWS
COMPANY NEWS
EVENTS
JOURNAL REVIEWS
JUNE 2026
NEWS
News Centre
NOVEMBER 2026
PRODUCT NEWS
SEPTEMBER 2026
Uncategorised
Uncategorized

About Us

Obs Gynae & Midwifery News (OGMN) is a leading trade title in the field of obstetrics, gynaecology, midwifery and women’s health

Having been at the forefront of this critical field for over a decade as its leading trade title, Obs Gynae & Midwifery News is now an exclusively digital platform.

AbbVie

NICE recommends first-in-class FRα ADC in platinum-resistant ovarian cancer

NICE recommends first-in-class FRα ADC in platinum-resistant ovarian cancer

Organon announces MHRA approval extending duration of use of NEXPLANON® (etonogestrel implant) 68 mg Radiopaque to 5 years

Central Medical Supplies continues support For Ickle Pickles Children’s Charity

Research looks into new approach to understand and detect endometriosis using menstrual blood

Fetal MRI pioneer honoured for services to women’s health

Newly identified symptoms may predict eclampsia risk in pregnancy

About Us

AbbVie

NICE recommends first-in-class FRα ADC in platinum-resistant ovarian cancer

and receive all of the latest news via our weekly newsletter

NICE recommends first-in-class FRα ADC in platinum-resistant ovarian cancer

Organon announces MHRA approval extending duration of use of NEXPLANON® (etonogestrel implant) 68 mg Radiopaque to 5 years

Central Medical Supplies continues support For Ickle Pickles Children’s Charity

Research looks into new approach to understand and detect endometriosis using menstrual blood

Fetal MRI pioneer honoured for services to women’s health

Newly identified symptoms may predict eclampsia risk in pregnancy

About Us

Subscribe

and receive all of the latest insurance claims news via our weekly newsletter